A Study of Contrast-enhanced EBUS in Lung Lesions and Intrathoracic Lymph Nodes
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-90
SponsorShanghai Chest Hospital
About this trial
Exploring the Clinical Application Value of Contrast Enhancement Features in CE-EBUS Images for the Diagnosis of Pulmonary Lesions and Intrapulmonary Lymph Nodes
Eligibility criteria
Qualifiers
Age >18 years old；
Enlargement of at least one intrathoracic LN (short diameter > 1 cm) or central parenchymal lung lesions adjacent to the airway detected on chest CT, or increased fluorodeoxyglucose uptake in at least one intrathoracic lymph node on PET / CT (standardized uptake value > 2.5)；
CP-EBUS-TBNA is required to determine the diagnosis or staging, the patient agreed to undergo CE-EBUS, and there were no contraindications to EBUS-TBNA;
Patients who have good compliance and sign informed consent.
Disqualifiers
Patients with known hypersensitivity to ultrasound contrast components;
Patients with severe pulmonary hypertension (pulmonary artery pressure > 90 mmHg);
Patients with angina pectoris, acute coronary syndrome, clinically unstable ischemic heart disease, heart failure, cardiac dysfunction, and cardiac disease with right-to-left shunting;
Patients with uncontrolled essential hypertension and adults with respiratory distress syndrome;
Trial design
Treatments tested in this trial
- Contrast-enhanced endobronchial ultrasound
Treatment groups
250 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov